Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2017 Oct 1;65(7):1085-1093.
doi: 10.1093/cid/cix505.

High Rate of Treatment Completion in Program Settings With 12-Dose Weekly Isoniazid and Rifapentine for Latent Mycobacterium tuberculosis Infection

Affiliations
Observational Study

High Rate of Treatment Completion in Program Settings With 12-Dose Weekly Isoniazid and Rifapentine for Latent Mycobacterium tuberculosis Infection

Amy L Sandul et al. Clin Infect Dis. .

Abstract

Background: Randomized controlled trials have demonstrated that the newest latent tuberculosis (LTBI) regimen, 12 weekly doses of directly observed isoniazid and rifapentine (3HP), is as efficacious as 9 months of isoniazid, with a greater completion rate (82% vs 69%); however, 3HP has not been assessed in routine healthcare settings.

Methods: Observational cohort of LTBI patients receiving 3HP through 16 US programs was used to assess treatment completion, adverse drug reactions, and factors associated with treatment discontinuation.

Results: Of 3288 patients eligible to complete 3HP, 2867 (87.2%) completed treatment. Children aged 2-17 years had the highest completion rate (94.5% [155/164]). Patients reporting homelessness had a completion rate of 81.2% (147/181). In univariable analyses, discontinuation was lowest among children (relative risk [RR], 0.44 [95% confidence interval {CI}, .23-.85]; P = .014), and highest in persons aged ≥65 years (RR, 1.72 [95% CI, 1.25-2.35]; P < .001). In multivariable analyses, discontinuation was lowest among contacts of patients with tuberculosis (TB) disease (adjusted RR [ARR], 0.68 [95% CI, .52-.89]; P = .005) and students (ARR, 0.45 [95% CI, .21-.98]; P = .044), and highest with incarceration (ARR, 1.43 [95% CI, 1.08-1.89]; P = .013) and homelessness (ARR, 1.72 [95% CI, 1.25-2.39]; P = .001). Adverse drug reactions were reported by 1174 (35.7%) patients, of whom 891 (76.0%) completed treatment.

Conclusions: Completion of 3HP in routine healthcare settings was greater overall than rates reported from clinical trials, and greater than historically observed using other regimens among reportedly nonadherent populations. Widespread use of 3HP for LTBI treatment could accelerate elimination of TB disease in the United States.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: None of the authors have any indirect or direct potential conflicts of interest to disclose.

Figures

Figure 1
Figure 1. Profile of Persons with Latent TB Infection Who Took 3HP
aTreatment reason per local policy are dichotomous factors: therefore, n does not equal 3288 bRecent contact of person with contagious TB cPerson with baseline tuberculin skin test who has ≥10mm increase in induration, or positive IGRA with a documented negative TB test, within a 2-year period Abbreviations: 3HP, a 3-month regimen of isoniazid and rifapentine; HAART, highly active antiretroviral treatment; HIV, human immunodeficiency virus; IGRA, interferon-gamma release assay; LTBI, latent tuberculosis infection; TB, tuberculosis.
Figure 2
Figure 2. Number and Percentage of Patients with Medication Reactions After any 3HP dose, n=1174a
a Patients could report ≥1 reaction, after ≥1 dose b Other symptoms reported by ≥1 patient includes dermatological-related symptoms, gastro-intestinal symptoms, cough, mental health symptoms, weight loss, blurred vision, flu-like symptoms, breathing issues, back pain, gynecologic symptoms, chest discomfort, diaphoresis, angioedema, bleeding, palpitations, easy bruising, swelling, neurologic symptoms, hypotension/near syncope and syncope, flushing, red eyes, upper respiratory infection, genitourinary symptoms, other eye symptoms, black stool, pain, pneumonia, and sepsis.

References

    1. Taylor Z, Nolan CM, Blumberg HM. Controlling tuberculosis in the United States: recommendations from the American Thoracic Society, CDC, and the Infectious Diseases Society of America. MMWR Recomm Rep. 2005;54 (RR-12) - PubMed
    1. Centers for Disease Control and Prevention. Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent Mycobacterium tuberculosis infection. MMWR Morb Mortal Wkly Rep. 2011;60(48):1650–1653. - PubMed
    1. Saukkonen J, Cohn D, Jasmer R, et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med. 2006;174(8):935–952. doi: 10.1164/rccm.200510-1666ST. - DOI - PubMed
    1. Sterling T, Villarino E, Borisov A, et al. TB Trials Consortium PREVENT TB Team. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med. 2011;365(23):2155–2166. doi: 10.1056/NEJMoa1104875. - DOI - PubMed
    1. Martinson N, Barnes G, Moulton L, et al. New regimens to prevent tuberculosis in adults with HIV infection. N Engl J Med. 2011;365(1):11–20. doi: 10.1056/NEJMoa1005136. - DOI - PMC - PubMed

Publication types

MeSH terms